INTRODUCTION
Multiple myeloma (MM) is a malignant B-cell neoplasm characterized by the aberrant expansion of plasma cells in bone marrow that secrete a monoclonal paraprotein, resulting in end-organ damage. 1 It is the second most common hematologic malignancy diagnosed in adults, with a prevalence of slightly >10%. The disease course is heterogeneous, with survival ranging from <1 year in patients with an aggressive presentation to >10 years in individuals with indolent disease. 2 Different patient characteristics, as well as disease biology and treatment regimens, have been identified as predictors of patient outcome, namely age, cytogenetic abnormalities, ß 2 -microglobulin level, and treatment with novel antimyeloma agents. 3 The potential contribution of socioeconomic factors to prognosis, in addition to the classic clinical prognostic variables, create a survival disparity observed across countries due to variations in access to and quality of cancer care. [4] [5] [6] Studies among patients with MM and other malignancies have reported the limiting effect of poverty on survival; these studies also have linked access to private health care or private insurance with an earlier diagnosis, better treatment, and longer survival outcomes. [5] [6] [7] [8] Novel agents in the treatment of MM, such as proteasome inhibitors and immunomodulatory drugs, have been incorporated with autologous stem cell transplantation (autoSCT) as initial therapy to improve response rates and survival over the past 20 years. 9 This improvement has been greater among younger patients and white patients compared with older patients and those who are ethnic minorities. [10] [11] [12] Success in using bortezomib and lenalidomide as first-line therapy, as recommended by international guidelines, has been achieved at a high financial cost. Treatment regimens including these novel agents have become difficult to access, mainly for patients living in low-income and middle-income countries (LMIC), where these drugs are not available to everyone who needs them. The majority of patients in these countries receive treatment regimens containing thalidomide as the only affordable "new" agent. 13 Similarly, access to high-dose chemotherapy followed by autoSCT, a well-recognized standard of care among eligible patients since the 1990s, is restricted in those areas of the world with limited resources.
14 Patients in Mexico receive health care from a system composed of the following 3 subsystems: 1) social security institutions that provide health services and nearly all medications for the formally employed and their families (approximately 60% of the population); 2) governmentfunded services headed by the Ministry of Health for the uninsured population, in which patients must pay at least part of the cost for services and medications due to a limited treatment package for certain high-cost diseases, excluding MM (30% of the population); and 3) a private sector financed out of pocket as well as the private insurance market, covering <10% of the population. 15, 16 To our knowledge to date, scarce data exist regarding how many patients in LMIC have access to the newest agents for the treatment of MM and how this impacts their outcomes. We considered it relevant to compare patients with MM who can afford private insurance and be treated according to the MM international guidelines with those managed in the public sector who do not have access to private health care insurance coverage and are treated with earlier generation drugs on an out-of-pocket basis.
MATERIALS AND METHODS
The current study included a retrospective review of the clinical records of all consecutive patients newly diagnosed with symptomatic MM from October 2007 to July 2016 at the University Hospital in Monterrey, Mexico. The University Hospital is a public academic center that provides medical care to a population that does not have access to social security institutions and a large percentage of patients with private health insurance.
The study was conducted in accordance with the institutional guidelines and received approval from the institutional review board of the School of Medicine, which waived informed consent from patients given the retrospective nature of the analysis. Clinical records were anonymized before analysis.
Patient medical records were reviewed to collect baseline and follow-up variables of interest, including sex, age, International Staging System (ISS) stage of disease, paraprotein type, cytogenetics, treatment, eligibility for autoSCT, response, disease recurrence or progression dates, and date of last follow-up or death. Diagnosis and treatment responses were assessed by the International Myeloma Working Group criteria. 17 We also obtained information regarding the primary source of payment to define 2 groups according to health insurance availability and analyzed them with regard to first-line treatment and transplantation eligibility. Data were updated on August 30, 2017.
A total of 166 patients were diagnosed during this period, 18 of whom were excluded: 8 patients were lost to follow-up before the first disease evaluation and 10 patients received care at another health care institution. Data from 148 patients remained available for this analysis and patients were divided into 2 cohorts based on the availability of health insurance. The first cohort consisted of 77 patients (52%) who did not have access to health care coverage and were treated on an out-of-pocket basis at public hospitals: the public cohort (PubC). The most common induction regimen in this group was cyclophosphamide at a dose of 500 mg weekly, thalidomide at a dose of 100 mg/day, and dexamethasone at a dose of 40 mg on days 1 to 4 of each 28-day cycle (CTD). 18, 19 The second cohort consisted of 71 insured patients (48%) who had health care expenses paid for through private insurance providers and were cared for within private health systems: the private cohort (PrivC). The most common induction regimen in this group was bortezomib, cyclophosphamide, and dexamethasone and bortezomib, thalidomide, and dexamethasone. 20 
Statistical Analysis
Baseline data are presented as the means with standard deviations (SDs) and medians with interquartile ranges (IQRs) for continuous variables and percentages for categorical variables. Differences were analyzed for significance between the 2 groups using a 2-sample Student t test or Wilcoxon rank sum test for continuous variables and the chi-square test or Fisher exact test for categorical variables. The median follow-up was estimated using the reverse Kaplan-Meier method. Survival curves were calculated according to the Kaplan-Meier method, and differences between curves were evaluated with the log-rank test. Progression-free survival (PFS) was defined as the time between the date MM was diagnosed and the date disease progression was detected. For patients who died, overall survival (OS) was measured in months from the date of diagnosis to the date of death from any cause. Patients who were alive at the end of the study were censored at the date of last known contact. Multivariate analysis was performed using the unadjusted and adjusted Cox proportional hazard regression model. Two-sided P values were considered to be statistically significant at P.05. All data were analyzed using SPSS statistical software (version 20; IBM Corporation, Armonk, New York). 
RESULTS
Baseline characteristics for each group are presented in Table 1 . Overall, the median age of the patients was 60 years (IQR, 54-71 years), approximately 35% were aged 55 years, and approximately 25% were aged 70 years. The male:female ratio was 1.27. The percentages of patients with ISS stage I, II, and III disease were 26%, 34%, and 40%, respectively. There were no statistically significant differences noted between the 2 groups in terms of median age, sex, heavy-chain subclass, light-chain isotype, anemia, or the percentage of patients eligible for autoSCT. Compared with those in the PrivC group, patients in the PubC group were more likely to be diagnosed with disease of an advanced ISS stage, to have a serum creatinine level >2 mg/ dL, and to have a serum calcium level >11.5 mg/dL.
The median follow-up for the 148 patients was 41 months (95% confidence interval [95% CI], 31-51 months). The length of follow-up was found to be significantly different between the groups: 57 months (95% CI, 42.9-73 months) for patients in the PrivC cohort and 30 months (95% CI, 18.7-41.2 months) for patients in the PubC cohort (P<.01). A higher overall response rate (ORR), including complete response, very good partial response, and partial response, was observed among patients in the PrivC group compared with those in the PubC group (Table 2) . A greater percentage of patients with early mortality (EM) was observed in the in PubC group; 10 patients in the PubC group (12.9%) and 3 patients in the PrivC group (4.2%) died within 12 months of diagnosis, whereas 7 patients and 2 patients, respectively, died within 6 months of diagnosis. The majority of patients with EM were aged >75 years and 4 younger patients with EM had renal insufficiency. The causes of death in patients with EM included pneumonia, other infections, and renal failure; the majority of these deaths were directly attributed to MM progression.
Patients in the PrivC group had a significantly longer median PFS (41 months; 95% CI, 27-54 months) compared with those in the PubC group (23 months; 95% CI, 16.2-29.7 months) and a significantly longer median OS (79 months [95% CI, 70-87 months] vs 51 months [95% CI, 37-64 months], respectively) (Fig. 1) . The median OS from the time of disease recurrence was 57 months (95% CI, 34-79 months) among patients in the PrivC cohort versus 24 months (95% CI, 13-34 months) for patients in the PubC cohort. The median respectively, for patients in the PrivC cohort and 21 months, 38 months, and 17%, respectively, for patients in the PubC cohort (Fig. 2 ).
Transplantation-Eligible Patients
A total of 48 patients (62%) in the PubC cohort and 45 patients (63%) in the PrivC cohort were considered suitable for autoSCT. The median age of the patients was 55 years (IQR, 46-59 years). The most common induction scheme before autoSCT in the PrivC cohort was bortezomib-based therapy, which was administered to 75% of patients. Melphalan-conditioned autoSCT was performed in 84% and 38%, respectively, of the patients in the PrivC and PubC cohorts for whom this procedure initially was planned, and the mean time to transplantation was 10 months (SD, 65 months) and 12 months (SD, 66 months), respectively, from diagnosis. Patients in the PrivC cohort achieved a superior response rate compared with those in the PubC cohort; the ORRs were 94% and 82%, respectively. All patients in the PubC cohort received maintenance therapy with thalidomide, whereas patients in the PrivC cohort received lenalidomide (35%), bortezomib twice monthly (27%), or thalidomide alone (18%) or in combination with steroids (8%). The remaining patients (12%) received no maintenance. With a median follow-up of 47 months (95% CI, 34-59 months), 57 patients (61%) had experienced disease progression and 61 (66%) remained alive. Significantly better survival was observed among patients in the PrivC cohort. The median PFS, OS, and 5-year OS rate were 41 months, 84 months, and 65%, respectively, for patients in the PrivC cohort and 25 months, 54 months, and 43%, respectively, for patients in the PubC cohort (Fig. 3) .
The results of cytogenetic studies were available for only 20% of all patients, and consequently no analysis was undertaken. Because ISS stage, renal failure, and hypercalcemia were found to be significantly different between groups, these variables were included in a Cox regression analysis for OS. Patients in the PubC cohort experienced a higher risk of death compared with those in the PrivC cohort (hazard ratio, 2.0; 95% CI, 1.0-4.3 [P 5 .04]) (Table 3) .
DISCUSSION
To the best of our knowledge, the current study is the first to examine differences between patients with MM with and without access to a health care system that provides standard MM treatment in a middle-income country. As expected, patients with newly diagnosed MM who received treatment within a private health care system had higher response rates and better survival compared with those who received care at a public hospital and had no access to novel agents and stem cell transplantation.
The socioeconomic conditions and availability of health insurance are major determinants of the differential use of health services and access to medications. In Mexico, the gross domestic product per capita in 2016 was $8201.31 US dollars (USD), which was considerably lower than that of the United States ($57,466.79 USD) and Spain ($26,528.49 USD).
Access to bortezomib and lenalidomide is very limited in the public health care system, from which the majority of patients with MM receive assistance, including both for patients with social security and those without insurance. Mexican patients with access to these drugs and private health care, which is paid for through the private insurance market, are a minority at <10%. 15, 16 Thus, few patients in the country benefit from advances in the treatment of MM.
The current study included PubC and PrivC patients at a ratio of nearly 1:1, rather than an "expected" ratio of 3:1, which is explained by the fact that we receive an excess of PrivC patients from the northeastern region of the country who choose their place of treatment, in contrast to PubC patients in our region, who for the most part are treated in local public hematology clinics.
Approved antimyeloma drugs in Mexico that are available for those with private insurance (or on an "outof-pocket" basis) include thalidomide, bortezomib, and lenalidomide as first-line treatment, carfilzomib and daratumumab as second-line treatment, and pomalidomide as third-line treatment. However, due to its cost, thalidomide is the most commonly used agent in public settings in the first-line therapy, whereas bortezomib continues to be reserved as a second-line therapy and lenalidomide is rarely used in those treated in social security institutions. Thus, access to novel antimyeloma agents is very limited in the Mexican public health care system, and many patients receive treatment regimens containing thalidomide as the only affordable newer agent.
There were striking differences noted with regard to clinical features at the time of diagnosis and treatment modalities between the 2 groups in the current study. One of the most significant differences was the high percentage of patients with advanced stage disease in the PubC compared with the PrivC cohort. In the current study, ISS stage III disease was observed in 51% of patients in the PubC cohort, which is a notably higher percentage compared with the PrivC cohort, as well as MM trials.
9,21-23 A delay in diagnosis likely contributed to the advanced stage of disease observed in patients in the PubC cohort due to patient-related factors such as low socioeconomic status and psychosocial factors, as well as those factors inherent in the health care system, such as restricted access to primary care.
Age is a major prognostic factor and indicator of treatment tolerance in patients with MM. In the current study, a nonsignificant difference in the median age between groups was observed; however, it is important to note that patients in the current study were younger than those reported when unselected patients are included. 24, 25 High-risk chromosomal abnormalities are associated with lower response rates and shorter survival times. 2 It should be noted that the cytogenetic status was not known for a majority of patients in the current study, and therefore it was not possible to assess its impact on the results reported herein. In addition, fluorescence in situ hybridization was not performed routinely in the current study patients because it is expensive and requires qualified centers, which are lacking in Mexico. Renal impairment was observed more frequently in patients in the PubC cohort compared with those in the PrivC cohort; this condition also could contribute to a higher mortality and shorter survival time in patients in the PubC cohort, as reported before the use of bortezomib. After controlling for disease stage and renal impairment, we still observed differences in survival; patients in the PubC cohort were found to have twice the risk of death as those in the PrivC group, suggesting that differences in treatment could have contributed to the worsened survival rates of patients in the PubC cohort. Similarly, in the United States, social determinants of health are believed to account for the higher risk of death associated with a lack of health insurance or being a Medicaid beneficiary. 5 As expected, a significantly higher ORR and improvement in survival for patients in the PrivC cohort were observed; the majority of the patients in this group received bortezomib as first-line therapy. In the current study, we chose to examine outcomes by using a timeline cutoff contemporaneous with the availability of newer agents. To the best of our knowledge, bortezomib-based induction regimens have been compared with nonbortezomib-based regimens in at least 4 cooperative group phase 3 studies and demonstrated significant improvements in postinduction and posttransplantation response rates, with substantial improvements in PFS noted. 23 Recently, further improvements were observed with double and triple combinations of novel agents that included bortezomib and are recommended for induction treatment in both patients who are candidates for and those who are not candidates for stem cell transplantation. 26 To our knowledge, clinical trials that have used CTD regimens as an induction regimen are scant. This triple-drug regimen has been used when there is no access to newer antimyeloma drugs other than thalidomide. 13, 14 To the best of our knowledge, the first report on the activity of CTD as first-line therapy was a retrospective study in the United Kingdom in which it was considered to have higher efficacy and a faster response than polychemotherapy (cyclophosphamide, vincristine, dexamethasone, and melphalan) in patients destined for autoSCT. 18 The same group reported a better response rate with attenuated CTD in patients determined to be unsuitable for autoSCT compared with melphalan and prednisone. 19 The results in the current study with a CTD induction regimen in patients in the PubC cohort were similar to these studies and only slightly better than those reported with thalidomide plus dexamethasone. 27 Patients who underwent autoSCT were found to have superior PFS and OS. The percentage of transplantation-eligible patients who underwent autoSCT was significantly higher in the PrivC cohort compared with the PubC one (84% vs 38%), a difference that also is explained by unaffordability, rather than a lack of availability. Even among patients in the PubC cohort, better PFS and OS were found among patients who underwent autoSCT. It is interesting to note that autoSCT still is of major importance in the treatment of this disease, regardless of the initial therapy. Longer survival after first disease recurrence in the PrivC group was found, and it was influenced by the use of different subsequent regimens; approximately 70% of patients in the PrivC cohort and 0% of patients in the PubC cohort received bortezomib, carfilzomib, lenalidomide, or pomalidomide as rescue therapy, whereas patients in the PubC cohort received thalidomidebased regimens for second-line and third-line therapy.
It should be noted that the current study was limited by its retrospective nature, sample size, and lack of predefined schedules for response assessment, and therefore it is difficult to accurately compare the responses observed with those in other studies.
The results of the current study confirm that a lack of health insurance coverage in an LMIC is a critical barrier to receiving newer generation MM drugs and related medical care that impacts prognosis. Stage at diagnosis, induction therapy, and autoSCT were found to contribute to survival disparities between patients treated in PubC and PrivC cohorts in Mexico. These findings underscore the need to improve the affordability of novel agents and stem cell transplantation in public health care service settings.
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